H.C. Wainwright analyst Jason Kolbert reiterated a Buy rating on Mesoblast Ltd (MESO) today and set a price target of $17. The company’s shares opened today at $5.25, close to its 52-week low of $4.74.
According to TipRanks.com, Kolbert is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.7% and a 33.0% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.
Currently, the analyst consensus on Mesoblast Ltd is a Strong Buy with an average price target of $17.75, a 238.1% upside from current levels. In a report issued on November 9, Maxim Group also maintained a Buy rating on the stock with a $16 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.78 and a one-year low of $4.74. Currently, Mesoblast Ltd has an average volume of 85K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.
